More on interferon-induced cutaneous necrosis.
Shinohara
K
K
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016898:Interferon-alpha / Q000009:adverse effects*; D016899:Interferon-beta / Q000009:adverse effects; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy; D009103:Multiple Sclerosis / Q000628:therapy; D009336:Necrosis; D012883:Skin Ulcer / Q000139:chemically induced*
D000970:Antineoplastic Agents; D016898:Interferon-alpha; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a